Biotechnology
Beyond GLP-1: Roche's $2.3B Bet on Muscle-Sparing Obesity Science
Roche commits $2.3 billion to Hanmi's UCN2 obesity drug candidate, signaling a strategic shift toward muscle-preserving mechanisms beyond GLP-1 agonists.
Markets
Biotechnology
Rewriting the Code Without Cutting It: What Epicrispr's FSHD Data Mean for Epigenetic Medicine
Epicrispr's EPI-321 produced measurable muscle growth in FSHD patients with a single dose, without altering DNA. The $90M Series C and early clinical data mark a potential inflection point for epigenetic medicine.
Pharmaceuticals
The Triple-G Black Market: What Lilly's Retatrutide Lawsuits Reveal About the GLP-1 Era
Eli Lilly filed six lawsuits against black-market sellers of retatrutide on August 12, 2026. The legal action reveals a deeper structural tension in the obesity drug market that litigation alone cannot resolve.
Pharmaceuticals
Beyond the Dual Agonist: What Retatrutide's Phase 3 Data Mean for the Future of Obesity Medicine
Eli Lilly's positive Phase 3 results for retatrutide show 22.6% average weight loss in patients with severe obesity and cardiovascular disease—a level historically associated with bariatric surgery. What the data mean for the future of obesity medicine.
Pharmaceuticals
When Off-Label Becomes Official: The Lytenava Approval and What It Means for the Retina Market
The FDA's approval of Lytenava formalizes what retina specialists have done off-label for over 20 years. The regulatory hurdle is cleared. The commercial one may prove harder.
Biotechnology
GSK's Jideytro Approval Is More Than a Drug Launch. It's a Statement About Where Oncology Is Heading.
GSK's FDA approval of Jideytro marks more than a drug launch—it signals the arrival of second-generation targeted therapies in oncology with meaningful clinical advantages over first-generation inhibitors.
Biotechnology
Samsung Biologics' $1.8B PolyPeptide Bet Is Really About the GLP-1 Supply Chain
Samsung Biologics' $1.81 billion bid for Swiss peptide manufacturer PolyPeptide Group is not just an M&A story. It is a strategic play for control of the GLP-1 drug supply chain, and a signal of where the CDMO industry is heading.
Pharmaceuticals
The Pill That Could Retire the Needle: What Lipfendra's Approval Means for Cholesterol Medicine
Merck's enlicitide becomes the first oral PCSK9 inhibitor approved by the FDA, potentially transforming cholesterol treatment by eliminating the need for injections.
Biotechnology
Beyond Jakafi: What Ipsen's $1.75 Billion Bet on Navtemadlin Means for Myelofibrosis Treatment
Ipsen's $1.75 billion acquisition of Kartos Therapeutics brings navtemadlin, a novel MDM2 inhibitor, to myelofibrosis patients who have failed ruxolitinib. The drug targets a complementary pathway with promising Phase 1b/2 data showing disease modification signals.
Pharmaceuticals
AbbVie's $10.9 Billion Bet on Zumilokibart Is About More Than Eczema
AbbVie's $10.9 billion acquisition of Apogee Therapeutics signals a strategic shift in immunology drug development. The deal centers on zumilokibart, a long-acting IL-13 inhibitor designed to compete with Dupixent through superior dosing convenience.
Biotechnology
The $670 Million Question: What Parabilis Tells Us About Biotech's New Confidence
Parabilis Medicines raised $670 million in the largest-ever venture-backed biotech IPO, breaking Moderna's eight-year record. We examine what the company's novel Helicon peptide platform and the market's appetite for it reveal about where drug discovery is heading.
Biotechnology
GSK's $10.6 Billion Nuvalent Bet Is a Statement About Where Precision Oncology Is Heading
GSK's $10.6 billion acquisition of Nuvalent Bio secures two near-approval precision oncology drugs for NSCLC and signals a broader strategic shift toward building a lung cancer franchise. We examine what the deal reveals about where targeted therapy is heading.